A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia

Hosonuma Kenichi; Sato Ken; Yamazaki Yuichi; Yanagisawa Masatoshi; Hashizume Hiroaki; Horiguchi Norio; Kakizaki Satoru; Kusano Motoyasu; Yamada Masanobu

首页> 外文期刊>The American Journal of Gastroenterology >A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia

【24h】

A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia

机译：熊去氧胆酸和苯扎贝特长期联合治疗原发性胆汁性肝硬化和血脂异常患者的前瞻性随机对照研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

OBJECTIVES: The aim of this study was to assess the long-term prognosis, efficacy, and safety of combination therapy using ursodeoxycholic acid (UDCA) and bezafibrate (BF) for primary biliary cirrhosis (PBC) patients exhibiting dyslipidemia.

机译：目的：本研究的目的是评估使用熊去氧胆酸（UDCA）和苯扎贝特（BF）联合治疗血脂异常的原发性胆汁性肝硬化（PBC）患者的长期预后，疗效和安全性。

著录项

来源
《The American Journal of Gastroenterology》 |2015年第3期|共9页
作者
Hosonuma Kenichi; Sato Ken; Yamazaki Yuichi; Yanagisawa Masatoshi; Hashizume Hiroaki; Horiguchi Norio; Kakizaki Satoru; Kusano Motoyasu; Yamada Masanobu;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia [J] . Hosonuma Kenichi, Sato Ken, Yamazaki Yuichi, The American Journal of Gastroenterology . 2015,第3期

机译：熊去氧胆酸和苯扎贝特长期联合治疗原发性胆汁性肝硬化和血脂异常患者的前瞻性随机对照研究
2. Combination Therapy of Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis: The End of the Steroid Era in Autoimmune Liver Diseases? Response [J] . Sato Ken, Hosonuma Kenichi, Kusano Motoyasu, The American Journal of Gastroenterology . 2015,第7期

机译：熊去氧胆酸和苯扎贝特联合治疗原发性胆汁性肝硬化：自身免疫性肝病中类固醇时代的终结？响应
3. Combination Therapy of Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis: The End of the Steroid Era in Autoimmune Liver Diseases? [J] . Licinio Raffaele, Facciorusso Antonio, Castellaneta Nicola Maurizio, The American Journal of Gastroenterology . 2015,第7期

机译：熊去氧胆酸和苯扎贝特联合治疗原发性胆汁性肝硬化：自身免疫性肝病中类固醇时代的终结？
4. Ursodeoxycholic Acid therapy Affects the Cytokine Network and Plays An Immunomodulatory Role in Patients With Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis [C] . M. G. Neuman, P. Angulo, I. M. Malkiewicz, Falk Symposium . 2003

机译：核糖核酸酸治疗影响细胞因子网络，并对初级硬化胆管炎和原发性胆汁肝硬化患者发挥免疫调节作用
5. Predicting outcomes post liver transplantation in patients with primary biliary cirrhosis and primary sclerosing cholangitis. [D] . Zapatochny Rufo, Rebecca Jo. 2003

机译：预测原发性胆汁性肝硬化和原发性硬化性胆管炎患者肝移植后的结局。
6. Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials [O] . Rohit Agrawal, Muhammad Majeed, Bashar M. Attar, 2019

机译：苯扎贝特和熊去氧胆酸在原发性胆源性胆管炎患者中的有效性：一项随机对照试验的荟萃分析
7. Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials [O] . Rohit Agrawal 2019

机译：贝兹鲜纤维素和熊甲酸胆酸在原发性胆管炎患者中的有效性：随机对照试验的荟萃分析

A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia

摘要

著录项

相似文献

相关主题

期刊订阅